Parsons, Rebecca L

Patient ID:

Specimen ID: **307-847-3679-0**



labcorp

Date Collected: **11/03/2025** Date Received: **11/03/2025** Date Reported: **11/08/2025** Fasting: **No**

Ordered Items: **TSH+T4F+T3Free+ThyAbs+TPO; IBD Expanded Panel; Testosterone,Free and Total; SARS-CoV-2 Semi-Quant Spike Ab; Trans. Growth Fact. beta 1*; Estradiol; Zinc, RBC; Reverse T3, Serum; Homocyst(e)ine; Allergens w/Total IgE Area 12; Progesterone; Melanocyte Stimulating Hormone; Cortisol - AM; Venipuncture**

Date Collected: **11/03/2025**

TSH+T4F+T3Free+ThyAbs+TPO

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
TSH [01]	1.840	1.470 04/11/2025	uIU/mL	0.450-4.500
T4,Free(Direct) [01]	1.14	1.03 04/11/2025	ng/dL	0.82-1.77
Triiodothyronine (T3), Free [01]	2.8		pg/mL	2.0-4.4
Thyroid Peroxidase (TPO) Ab [01]	16		IU/mL	0-34
Thyroglobulin Antibody [02]	<1.0		IU/mL	0.0-0.9

Thyroglobulin Antibody measured by Beckman Coulter Methodology
It should be noted that the presence of thyroglobulin antibodies may not be pathogenic nor diagnostic, especially at very low levels. The assay manufacturer has found that four percent of individuals without evidence of thyroid disease or autoimmunity will have positive TgAb levels up to 4 IU/mL.

IBD Expanded Panel

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
gASCA [03]	23		units	0-50
	Negative: <45 Equivocal: 45-50 Positive: >50			
ACCA [03]	17		units	0-90
	Negative: <80 Equivocal: 80-90 Positive: >90			
ALCA [03]	12		units	0-60
	Negative:<55 Equivocal: 55-60 Positive: >60			
▲ **AMCA** [03]	**236** **High**		units	0-100
	Negative: <90 Equivocal: 90-100 Positive: >100 This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.			
Atypical pANCA [03]	Negative			Negative
▶ **Comments**	**Abnormal**			

Suggestive of Crohn's Disease. Pattern is not conclusive for disease behavior risk stratification.

Testosterone,Free and Total

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Testosterone [01]	9	**3** 04/11/2025	ng/dL	4-50
Free Testosterone(Direct) [04]	0.4	0.2 04/11/2025	pg/mL	0.0-4.2

Date Collected: **11/03/2025**

SARS-CoV-2 Semi-Quant Spike Ab

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
SARS-CoV-2 Semi-Quant Spike Ab [A, 01]	See Dilution		U/mL	Negative<0.8
SARS-CoV-2 Spike Ab Dilution [A, 01]	9683		U/mL	Negative<0.8
SARS-CoV-2 Spike Ab Interp [A, 01]	Positive			

Antibodies against the SARS-CoV-2 spike protein receptor binding domain (RBD) were detected. It is yet undetermined what level of antibody to SARS-CoV-2 spike protein correlates to immunity against developing symptomatic SARS-CoV-2 disease. Studies are underway to measure the quantitative levels of specific SARS-CoV-2 antibodies following vaccination. Such studies will provide valuable insights into the correlation between protection from vaccination and antibody levels.
Roche Elecsys Anti-SARS-CoV-2 S

Trans. Growth Fact. beta 1*

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Trans. Growth Fact. beta 1* [05]	3252		pg/mL	2537-22306

The reference range was obtained from a limited population of apparently healthy adults and does not represent diagnostic thresholds. Compromised samples can produce falsely elevated results.
TGF-b1 results are directly affected by sample quality. Samples must be collected by venipuncture and processed to be platelet poor. Indicators of poor sample quality or improper processing may include hemolysis. Test methodology is microfluidics ELISA.
*This test was developed and its performance characteristics determined by Eurofins Viracor. It has not been cleared or approved by the U.S. Food and Drug Administration.

FLAG Interpretation: A = Abnormal, H = High, L = Low

Estradiol

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Estradiol [01]	73.5		pg/mL	

Adult Female	Range
Follicular phase	12.5 - 166.0
Ovulation phase	85.8 - 498.0
Luteal phase	43.8 - 211.0
Postmenopausal	<6.0 - 54.7
Pregnancy	
1st trimester	215.0 - >4300.0

Roche ECLIA methodology

Zinc, RBC

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Zinc, RBC [B, 03]	1235		ug/dL	1005-1559

Reverse T3, Serum

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Reverse T3, Serum [06]	12.8		ng/dL	

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Reference Range:
>15y: 9.2 - 24.1

Homocyst(e)ine

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Homocyst(e)ine [01]	5.8		umol/L	0.0-14.5

Allergens w/Total IgE Area 12

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Class Description [04]				

Levels of Specific IgE	Class	Description of Class
< 0.10	0	Negative
0.10 - 0.31	0/I	Equivocal/Low
0.32 - 0.55	I	Low
0.56 - 1.40	II	Moderate
1.41 - 3.90	III	High
3.91 - 19.00	IV	Very High
19.01 - 100.00	V	Very High
>100.00	VI	Very High

Immunoglobulin E, Total [04]	14		IU/mL	6-495
D001-IgE D pteronyssinus [04]	<0.10		kU/L	Class 0
D002-IgE D farinae [04]	<0.10		kU/L	Class 0
E001-IgE Cat Dander [04]	<0.10		kU/L	Class 0
E005-IgE Dog Dander [04]	<0.10		kU/L	Class 0
G002-IgE Bermuda Grass [04]	<0.10		kU/L	Class 0
G005-IgE Rye Grass, Perennial [04]	<0.10		kU/L	Class 0
G010-IgE Johnson Grass [04]	<0.10		kU/L	Class 0
I006-IgE Cockroach, German [04]	<0.10		kU/L	Class 0
M001-IgE Penicillium chrysogen [04]	<0.10		kU/L	Class 0
M002-IgE Cladosporium herbarum [04]	<0.10		kU/L	Class 0
M003-IgE Aspergillus fumigatus [04]	<0.10		kU/L	Class 0
M006-IgE Alternaria alternata [04]	<0.10		kU/L	Class 0
T009-IgE Olive Tree [04]	<0.10		kU/L	Class 0
T006-IgE Cedar, Mountain [04]	<0.10		kU/L	Class 0
T007-IgE Oak, White [04]	<0.10		kU/L	Class 0
T008-IgE Elm, American [04]	<0.10		kU/L	Class 0
T014-IgE Cottonwood [04]	<0.10		kU/L	Class 0

Allergens w/Total IgE Area 12 (Cont.)

T019-IgE Mimosa/Acacia [04]	<0.10	kU/L	Class 0
W001-IgE Ragweed, Short [04]	<0.10	kU/L	Class 0
W006-IgE Mugwort [04]	<0.10	kU/L	Class 0
W011-IgE Thistle, Russian [04]	<0.10	kU/L	Class 0
W014-IgE Pigweed, Common [04]	<0.10	kU/L	Class 0
E072-IgE Mouse Urine [04]	<0.10	kU/L	Class 0

Progesterone

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Progesterone [01]	9.8	1.5 04/11/2025	ng/mL	

```
Follicular phase          0.1 -   0.9
Luteal phase              1.8 -  23.9
Ovulation phase           0.1 -  12.0
Pregnant
   First trimester       11.0 -  44.3
   Second trimester      25.4 -  83.3
   Third trimester       58.7 - 214.0
Postmenopausal            0.0 -   0.1
```

Melanocyte Stimulating Hormone

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Melanocyte Stimulating Hormone [03]	11		pg/mL	0-40

Results for this test are for research purposes only by the assay's manufacturer. The performance characteristics of this product have not been established. Results should not be used as a diagnostic procedure without confirmation of the diagnosis by another medically established diagnostic product or procedure.

Cortisol - AM

Test	Current Result and Flag	Previous Result and Date	Units	Reference Interval
Cortisol - AM [01]	15.6		ug/dL	6.2-19.4

Previous Result
The Previous Result is listed for the most recent test performed by Labcorp in the past 5 years where there is sufficient patient demographic data to match the result to the patient. Results from certain tests are excluded from the Previous Result display.

Icon Legend
▲ Out of Reference Range ■ Critical or Alert

Footnotes/Disclaimers
A: This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. This test has been authorized only for detecting the presence of antibodies against SARS-CoV-2, not for any other viruses or pathogens.
B: This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.

Performing Labs

01: PDLCA - Labcorp Phoenix, 5005 S 40th Street Ste 1200, Phoenix, AZ 85040-2969 Dir: Earle Collum, MD
02: SPOWA - Labcorp Spokane, 110 W Cliff Dr. Ste 100-200, Spokane, WA 99204-3614 Dir: Shefali Goyal, MD
03: BN - Labcorp Burlington, 1447 York Court, Burlington, NC 27215-3361 Dir: Sanjai Nagendra, MD
04: CETWE - Labcorp Phoenix, 5005 S 40th Street Ste 1200, Phoenix, AZ 85040-2969 Dir: Earle Collum, MD
05: EURKS - Eurofins Viracor LLC, 18000 W 99th Street, Suite 10, Lenexa, KS 66219-1233 Dir: BROCK Neil, PhDBC
06: ES - Esoterix Inc, 4301 Lost Hills Road, Calabasas Hills, CA 91301-5358 Dir: Basel Kashlan, MD
For inquiries, the physician may contact Branch: 888-522-2677 Lab: 800-788-9743

[redacted]